Metformina Stadafarma Stadafarma

Metformin Hydrochloride, the active ingredient in Metformina Stadafarma, is a biguanide presented as an oral dosage form for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus, helping to lower fasting plasma glucose and HbA1c levels while also offering benefits in weight management.

GNH USA supplies Metformina Stadafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and timely delivery across multiple regions globally.

Metformina Stadafarma (metformin) acts on glucose metabolism in type 2 diabetes and related insulin‑resistant conditions. - Type 2 diabetes mellitus: improves blood glucose control and reduces HbA1c. - Prediabetes: delays progression to overt diabetes by enhancing insulin sensitivity. - Polycystic ovary syndrome: reduces insulin resistance and may improve menstrual regularity.

Metformina Stadafarma may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite. - Diarrhea: frequent loose stools, especially during treatment initiation. - Metallic taste: transient alteration in taste perception. - Vitamin B12 deficiency: decreased absorption with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: life‑threatening accumulation of lactate, requiring immediate medical attention. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: signs of liver injury including jaundice.

When prescribing Metformina Stadafarma, clinicians should consider several precautionary measures to minimise risk. - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic status: evaluate liver function, as impairment may increase risk of lactic acidosis. - Risk of lactic acidosis: avoid use in patients with conditions predisposing to hypoxia or severe infection. - Concomitant drugs: review for agents that may affect metformin clearance, such as cimetidine. - Elderly patients: start with lower dose and monitor tolerance closely. - Store at room temperature: keep tablets in the original container, protect from moisture and heat.

Metformina Stadafarma can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate lactic acidosis; discontinue metformin before imaging. - Cimetidine: reduces renal clearance, increasing metformin plasma levels. - Alcohol excess: heightens risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Thiazide diuretics: can increase risk of hyperglycaemia.